<?xml version="1.0" encoding="UTF-8"?>
<root>
    <author>ENA</author>
    <category>Sectors</category>
    <date>2024-10-10 17:04:32</date>
    <fulldesc>&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;&lt;strong&gt;New Delhi, Oct 10 (KNN)&lt;/strong&gt; In a recent development, India's Drugs Controller General (DCGI) has ordered the recall of approximately 45 medicines due to quality concerns, while initiating action against manufacturers of five spurious drugs. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;This information was disclosed by DCGI Rajeev Singh Raghuvanshi during the CII Pharma and Life Sciences summit in New Delhi on October 9, 2024.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Raghuvanshi clarified that recent reports of  50 fake medicines  being banned were inaccurate. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;He emphasised the distinction between  not of standard quality  medicines and fake or spurious drugs, stating that only five of the identified products were categorised as spurious under official terminology.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;The Central Drugs Standard Control Organisation (CDSCO) conducts monthly sampling and testing of over 2,000 market samples. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Typically, 40-50 of these fail to meet certain parameters, which may include minor issues not posing significant health risks. These findings are routinely published on the organisation's portal.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Upon identification of substandard or spurious drugs, the CDSCO immediately initiates a recall process, informing manufacturers to withdraw the products from the market. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;For the five spurious drugs identified, authorities are currently mapping the supply chain to trace and penalise those responsible for their distribution.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;Raghuvanshi assured that the Drug and Cosmetics Act provides comprehensive measures to address issues related to fake and spurious drugs. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;The CDSCO follows established procedures to investigate such cases, which may result in recommendations for prosecution or administrative actions, depending on the severity of non-compliance.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;This announcement follows last month's publication of CDSCO's monthly list, which included over 50 drugs, such as antacids and paracetamol, identified as substandard or fake medicines in the Indian market. &lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;The DCGI's statements aim to provide clarity on the regulatory actions being taken to ensure drug quality and safety in India.&lt;/span&gt;&lt;/p&gt;&#13;
&#13;
&lt;p&gt;&lt;span style=&quot;font-size:14px&quot;&gt;&lt;em&gt;&lt;strong&gt;(KNN Bureau)&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&#13;
</fulldesc>
    <id>39561</id>
    <link>https://knnindia.co.in/news/newsdetails/sectors/dcgi-orders-recall-of-45-medicines-over-quality-concerns</link>
    <pubDate>2024-10-10 17:04:32</pubDate>
    <source>knnindia.co.in</source>
    <title>DCGI Orders Recall Of 45 Medicines Over Quality Concerns</title>
</root>
